Department of Oral Medicine, Peking University School and Hospital of Stomatology, Beijing, China.
Department of Stomatology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
Sci Rep. 2017 Sep 19;7(1):11890. doi: 10.1038/s41598-017-12255-0.
Glucocorticoid (GC) resistance is the major obscule in the treatment of pemphigus vulgaris (PV) for both patients and clinicans with unclear mechanism. A hypotheis for this resistance is the mutations or polymorphisms present in the nuclear receptor subfamily 3, group C, member 1 (NR3C1) gene that encodes receptors for steroid hormones. This study aimed to investigate the association between NR3C1 gene polymorphisms and GC effectiveness in PV patients. 94 PV patients (64 GC-sensitive and 30 GC-resistant) and 100 healthy volunteers were enrolled in this case-control study. The genotyping of single nucleotide polymorphisms (SNPs) in BCL1, Arg23Lys, Asn363Ser 1548 t-insert, and le747Met, together with tag-SNP sites of the NR3C1 gene were evaluated. No significant differences were observed in genotypic and allelic frequencies of the 16 SNPs between PV patients and healthy volunteers. However, SNPs rs 11745958 C/T (OR: 8.95) and rs17209237 A/G (OR: 4.07) may be associated with an increased risk of GC resistance, while rs 33388 A/T (OR: 0.45) and rs7701443 A/G (OR: 0.51) may indicate a decreased risk of GC resistance in PV patients. NR3C1 gene variation may be associated with GC resistance in PV patients. More extensive genetic analyses and mechanistic analysis are required for further exploration.
糖皮质激素(GC)抵抗是治疗寻常型天疱疮(PV)的主要障碍,患者和临床医生都不清楚其机制。这种抵抗的一个假设是核受体亚家族 3、C 组、成员 1(NR3C1)基因的突变或多态性,该基因编码类固醇激素受体。本研究旨在探讨 NR3C1 基因多态性与 PV 患者 GC 疗效的关系。94 例 PV 患者(64 例 GC 敏感和 30 例 GC 耐药)和 100 名健康志愿者纳入本病例对照研究。评估了 BCL1、Arg23Lys、Asn363Ser1548t-插入和 le747Met 单核苷酸多态性(SNP)以及 NR3C1 基因的标签 SNP 位点的基因分型。PV 患者和健康志愿者之间 16 个 SNP 的基因型和等位基因频率无显著差异。然而,rs11745958C/T(OR:8.95)和 rs17209237A/G(OR:4.07)可能与 GC 耐药风险增加相关,而 rs33388A/T(OR:0.45)和 rs7701443A/G(OR:0.51)可能表明 PV 患者 GC 耐药风险降低。NR3C1 基因变异可能与 PV 患者 GC 耐药有关。需要进一步的遗传分析和机制分析来进一步探讨。